Trial of Afatinib (BIBW 2992) in Suspected or Confirmed Mutant EGFR Lung Cancer Patients Unfit for Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2016
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TIMELY
- 26 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2017.
- 18 Sep 2015 Accrual to date is 105% according to the United Kingdom Clinical Research Network record.
- 01 Sep 2015 Planned End Date changed from 1 Jun 2016 to 1 Aug 2016 as per ClinicalTrials.gov record.